The infectious diseases market is forecast to grow at 5.7% CAGR between 2023 and 2029 to reach $150bn in annual sales. The key players: Pfizer, Gilead Sciences and GSK, are expected to collectively generate 62% of total sales.
Artificial intelligence (AI) has been attracting negative headlines in recent months. But from a manufacturing perspective such technology is indispensable for firms seeking to remain competitive in their respective industry sectors. With advances in AI and the Internet of Things (IoT), the manufacturing sector is undergoing a transformative shift.
For most of human history, bacterial infections have been a leading cause of disease and death. Given this, it is hardly surprising that antibacterial treatments have been developed many times by different cultures at different points in human history.